Celon Pharma SA logo

CLN - Celon Pharma SA Share Price

PLN33.3 -2.0  -5.7%

Last Trade - 26/10/20

Sector
Healthcare
Size
Small Cap
Market Cap £297.0m
Enterprise Value £294.1m
Revenue £24.0m
Position in Universe 85th / 745
Bullish
Bearish
Unlock CLN Revenue
Momentum
Relative Strength (%)
1m -17.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 126.7 128.8 107.1 125.2 102.2 164.2 176.6 -5.2%
-7.6 -49.0 +15.0 -61.0 +125.1 +69.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Celon PharmaSA revenues increased 36% to PLN69.9M. Net income increasedfrom PLN8.2M to PLN20.8M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Net income benefited from Saleof Assets increase of 20% to PLN304K (income), OtherOperating Expenses decrease of 33% to PLN41K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CLN Revenue Unlock CLN Revenue

Net Income

CLN Net Income Unlock CLN Revenue

Normalised EPS

CLN Normalised EPS Unlock CLN Revenue

PE Ratio Range

CLN PE Ratio Range Unlock CLN Revenue

Dividend Yield Range

CLN Dividend Yield Range Unlock CLN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CLN EPS Forecasts Unlock CLN Revenue
Profile Summary

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated October 25, 2012
Public Since April 13, 2009
No. of Shareholders: n/a
No. of Employees: 440
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Warsaw Stock Exchange
Shares in Issue 45,000,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CLN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CLN
Upcoming Events for CLN
Frequently Asked Questions for Celon Pharma SA
What is the Celon Pharma SA share price?

As of 26/10/20, shares in Celon Pharma SA are trading at PLN33.3, giving the company a market capitalisation of £297.0m. This share price information is delayed by 15 minutes.

How has the Celon Pharma SA share price performed this year?

Shares in Celon Pharma SA are currently trading at PLN33.3 and the price has moved by -18.88% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celon Pharma SA price has moved by -9.49% over the past year.

What are the analyst and broker recommendations for Celon Pharma SA?

Of the analysts with advisory recommendations for Celon Pharma SA, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Celon Pharma SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Celon Pharma SA next release its financial results?

Celon Pharma SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Celon Pharma SA dividend yield?

The Celon Pharma SA dividend yield is 0.24% based on the trailing twelve month period.

Does Celon Pharma SA pay a dividend?

Last year, Celon Pharma SA paid a total dividend of 0.08, and it currently has a trailing dividend yield of 0.24%. Looking ahead, Celon Pharma SA has not announced an ex-dividend date yet.

When does Celon Pharma SA next pay dividends?

Celon Pharma SA has yet to annouce their ex-dividend date. The historic dividend yield on Celon Pharma SA shares is currently 0.24%.

How do I buy Celon Pharma SA shares?

To buy shares in Celon Pharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Celon Pharma SA?

Shares in Celon Pharma SA are currently trading at PLN33.3, giving the company a market capitalisation of £297.0m.

Where are Celon Pharma SA shares listed? Where are Celon Pharma SA shares listed?

Here are the trading details for Celon Pharma SA:

Country of listing: Poland
Exchange: WSE
Ticker Symbol: CLN
What kind of share is Celon Pharma SA?

Based on an overall assessment of its quality, value and momentum, Celon Pharma SA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Celon Pharma SA share price forecast 2020?

Shares in Celon Pharma SA are currently priced at PLN33.3. At that level they are trading at 25.68% discount to the analyst consensus target price of 0.00.

Analysts covering Celon Pharma SA currently have a consensus Earnings Per Share (EPS) forecast of 0.575 for the next financial year.

How can I tell whether the Celon Pharma SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celon Pharma SA. Over the past six months, the relative strength of its shares against the market has been -5.08%. At the current price of PLN33.3, shares in Celon Pharma SA are trading at -14.45% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Celon Pharma SA PE Ratio?

The Celon Pharma SA PE ratio based on its reported earnings over the past 12 months is 62.55. The shares are currently trading at PLN33.3.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Celon Pharma SA?

Celon Pharma SA's management team is headed by:

Maciej Wieczorek - CMG
Iwona Giedronowicz - CFO
Michal Kowalczewski - IND
Urszula Wieczorek - SUB
Robert Rzeminski - CSU
Artur Wieczorek - SUB
Krzysztof Kaczmarczyk - IND
Jacek Glinka - VMG
Who are the major shareholders of Celon Pharma SA?

Here are the top five shareholders of Celon Pharma SA based on the size of their shareholding:

Wieczorek (Maciej) Individual Investor
Percentage owned: 66.67% (30.0m shares)
Generali Otwarty Fundusz Emerytalny Pension Fund Portfolio
Percentage owned: 10.26% (4.62m shares)
Generali PTE S.A. Pension Fund
Percentage owned: 8.79% (3.96m shares)
Investors Towarzystwo Funduszy Inwestycyjnych S.A. Investment Advisor
Percentage owned: 3.82% (1.72m shares)
MetLife Powszechne Towarzystwo Emerytalne S.A. Pension Fund
Percentage owned: 3.28% (1.47m shares)
Similar to CLN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.